Compare CREG & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CREG | LTRN |
|---|---|---|
| Founded | N/A | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 31.5M |
| IPO Year | 2019 | 2020 |
| Metric | CREG | LTRN |
|---|---|---|
| Price | $0.34 | $2.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 4.7M | 46.1K |
| Earning Date | 03-27-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $867,431.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12953.89 | N/A |
| 52 Week Low | $0.20 | $2.24 |
| 52 Week High | $2.66 | $5.74 |
| Indicator | CREG | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 17.24 | 26.84 |
| Support Level | $0.20 | N/A |
| Resistance Level | $1.47 | $3.65 |
| Average True Range (ATR) | 0.26 | 0.17 |
| MACD | -0.08 | -0.04 |
| Stochastic Oscillator | 5.21 | 5.41 |
Smart Powerr Corp is a pioneer in waste energy recycling and a developer of energy efficiency solutions for various energy-intensive industries in China. It uses the Build-Operate-Transfer (BOT) model to provide energy-saving and recovery facilities for multiple energy-intensive industries in China. Its waste energy recycling projects allow customers which use substantial amounts of electricity to recapture previously wasted pressure, heat, and gas from their manufacturing processes to generate electricity. The company offers waste energy recycling systems to companies for use in nonferrous metal plants. It constructs its projects at its customer's facility and the electricity produced is used on-site by the customer.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.